MC1568|cas:852475-26-4|西域试剂

MC1568,97.31%

产品编号：Bellancom-16914| CAS NO：852475-26-4| 分子式：C₁₇H₁₅FN₂O₃| 分子量：314.31

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-16914	￥500.00	杭州北京（现货）
Bellancom-16914	￥1500.00	杭州北京（现货）
Bellancom-16914	￥2800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MC1568

产品介绍

MC1568是组蛋白脱乙酰酶(HDAC II)的抑制剂，可用于癌症研究。

生物活性

MC1568 is a selective class II (IIa) histone deacetylas (HDAC II) inhibitor, used for cancer research.

体外研究

MC1568 arrests myogenesis by decreasing myocyte enhancer factor 2D (MEF2D) expression, by stabilizing the HDAC4–HDAC3–MEF2D complex, and paradoxically, by inhibiting differentiation-induced MEF2D acetylation. MC1568 and MC1575 inhibits IL-8 levels and cell proliferation in either unstimulated or PMA-stimulated melanoma cells. They acts by suppressing c-Jun binding to the IL-8 promoter, recruitment of histones 3 and 4, RNA polymerase II and TFIIB to the c-Jun promoter, and c-Jun expression. MC1568 interferes with the RAR- and PPARγ-mediated differentiation-inducing signaling pathways. In F9 cells, this inhibitor specifically blocks endodermal differentiation. In 3T3-L1 cells, MC1568 attenuates PPARγ-induced adipogenesis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

MC1568 shows an apparent tissue-selective HDAC inhibition. In skeletal muscle and heart, MC1568 inhibits the activity of HDAC4 and HDAC5 without affecting HDAC3 activity, thereby leaving MEF2–HDAC complexes in a repressed state. MC1568 increases mortality and lesion volume and did not improve functional outcome. In addition, MC1568 decreases microtubule associated protein 2, phosphorylated neurofilament heavy chain and myelin basic protein immunoreactivity in the periinfarct cortex^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 18.5 mg/mL (58.86 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1816 mL	15.9079 mL	31.8157 mL
5 mM	0.6363 mL	3.1816 mL	6.3631 mL
10 mM	0.3182 mL	1.5908 mL	3.1816 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 17% Polyethylene glycol 12-hydroxystearate in saline
Solubility: 2.5 mg/mL (7.95 mM); Suspended solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 1 mg/mL (3.18 mM); Suspended solution; Need ultrasonic

此方案可获得 1 mg/mL (3.18 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液